Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

Science Corporation has implanted its PRIMA vision chip into the first patient with Stargardt disease, CEO Max Hodak said onstage at TechCrunch Disrupt. The company says the implant was placed in May as part of an ongoing trial at the Sydney Eye Hospital in Australia. During the patient's first rehabilitation session he saw a letter, and in the second he was able to read a word.
Stargardt disease is an inherited eye condition that progressively destroys central vision. It affects the outer retina, causing the light-sensing cells to die while potentially leaving the inner retina intact — the layer that passes visual signals onward to the brain. The result is a central blind spot that enlarges over time. Around 150,000 people worldwide have lost vision to the disease, and it is currently considered incurable.
PRIMA is built around a simple premise that Hodak described at the event: vision, as far as the brain is concerned, is electrical activity traveling down the optic nerve. If the optic nerve can be made to signal the rest of the brain correctly, sight can be restored. The device acts as a kind of artificial photoreceptor. A roughly hourlong procedure places a small chip in the back of the eye where photoreceptors have degenerated. The patient then wears camera-equipped glasses that capture a view of the world and transmit it to the implant.
The current implant is two millimeters by two millimeters, and Hodak was blunt about what that means for the user. He compared the experience to looking through a straw: black and white rather than color, not a wide field of view, but sharp and high-contrast, enough to make out a couple of letters at a time, in a patch of central vision. The company's stated next step is a larger field of view, which requires dealing with the curvature of the eye, plus smaller electrodes to approach native levels of detail. Hodak said a next-generation device is being worked on and should be in humans within the next year, and that over the next five years he expects the technology to get fairly close to native acuity.
The immediate commercial foothold is in Europe, where PRIMA is available for patients who have lost sight to geographic atrophy, an advanced form of age-related macular degeneration. The Stargardt work extends that into a different disease. Science Corporation argues its approach can be applied across multiple conditions, and Stargardt is a natural candidate because the inner retina may survive even as the outer retina degenerates — meaning there can still be a healthy pathway for the chip to stimulate.
Hodak, the former president and co-founder of Neuralink, founded Science Corporation in 2021 after leaving that company. He used the Disrupt stage to place PRIMA inside a much larger ambition. The retina, he noted, is part of the central nervous system, and he grouped cochlear implants, retinal prostheses and motor prostheses together as different kinds of brain-computer interfaces. That framing stretches the usual meaning of BCI, which in most public discussion refers to implanted electrodes that let a person control a computer or prosthetic. Hodak's version is broader: medical devices that read from or write to the nervous system.
That distinction matters for how Science Corporation is pursuing its core BCI program. The company has previously said its sensor sits inside the skull and rests on top of the brain, rather than being inserted directly into brain tissue the way Neuralink's device is. The company has suggested the approach could help with neurological conditions, including monitoring neurological activity in patients with brain tumors.
Hodak said the company's first clinical indication — which has not been announced publicly — is a neurodegenerative disease that everyone has heard of. Stroke is another area under consideration. His example: if part of the brain has died after a stroke, connections into the deep brain in two separate areas could allow new cortical areas to be added, something he said conventional electrodes cannot do. Longer term, he described the company's mission as understanding how the brain creates the mind and learning to build engineered brains.
On adoption, Hodak said Science Corporation expects many people will eventually use some kind of BCI. He was explicit that the company is not designing for healthy 40-year-olds, but he argued people will eventually need some kind of BCI by the age of 60 or 70. The framing he returned to was extending health span, not just lifespan.
The vision work, then, is both a product line and a proving ground. Science Corporation has said it wants to demonstrate that its methods work and build a sustainable business before pushing further into brain interfaces, and restoring sight in the visually impaired gives it a clinical pathway with measurable outcomes — letters and words read — while the harder neural engineering matures.
Why it matters: For developers and product teams tracking neurotechnology, PRIMA shows the field's near-term revenue and evidence are likely to come from sensory restoration in well-understood disease populations rather than from general-purpose brain interfaces. The reported benchmark here is modest and specific — a letter, then a word — which is the kind of granular outcome that sets expectations for what these implants can do today. If the next-generation implant reaches humans within a year as stated, the comparison points to watch will be field of view, electrode density and acuity rather than headline patient counts. This is my reading of the stated facts, not a company claim.
Based on reporting from the original publisher. Visit the source for full context and later updates.
Publisher excerpt
Max Hodak, the former president and co-founder of Neuralink, detailed onstage at TechCrunch Disrupt how his company's work with PRIMA is part of its path toward a novel brain-computer interface (BCI).